Construction of HER2-Specific HIV-1-Based VLPs

Area of Science:

• Nanotechnology
• Virology
• Biotechnology

Background:

• Virus-like particles (VLPs) are self-assembling protein nanostructures derived from viral components, lacking genetic material.
• VLPs are versatile nanoplatforms for applications in vaccines, drug delivery, and imaging.
• Targeting specific cells, such as cancer cells, requires engineered molecules to direct nanoparticles.

Purpose of the Study:

• To produce and characterize human immunodeficiency virus (HIV)-1 based VLPs displaying a single-chain variable fragment (scFv) targeting the human epidermal growth factor receptor 2 (HER2).
• To evaluate the potential of these engineered VLPs as non-toxic carriers for drug and/or imaging agent delivery.

Main Methods:

• Construction of a vector encoding an anti-HER2 scFv fused to HIV protein gp41.
• Production of HIV-1 based VLPs incorporating the engineered fusion protein.
• Characterization of the resulting VLPs for expression and structural integrity.

Main Results:

• Successful production of HIV-1 based VLPs displaying the anti-HER2 scFv.
• Early characterization data indicate the feasibility of expressing the engineered protein on the VLP surface.
• The developed VLPs demonstrate potential for targeted delivery applications.

Conclusions:

• Engineered HIV-1 based VLPs displaying an anti-HER2 scFv are producible and characterizable.
• These targeted VLPs represent promising, non-toxic nanoplatforms for future drug and imaging agent delivery systems.
• Further studies are warranted to validate their efficacy in preclinical models.